- Benzinga•10 days ago
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) revealed its final stage study of recombinant human beta-Glucuronidase has met the primary endpoint of reduction in urinary CAG excretion. According to the ...
Ultragenyx Pharmaceutical Inc.NasdaqGS
After hours: 53.730.00 (0.00%) as of 5:01 PM EDT
|Bid||52.46 x 100|
|Ask||53.73 x 1600|
|52wk Range||46.52 - 133.40|
|Day's Range||51.89 - 53.96|
|Avg Vol (3m)||700,180|
As of 4:00 PM EDT. Market closed.